Videos

Yelena Janjigian, MD, discussed the recent subgroup analysis from the MATTERHORN study, evaluating durvalumab plus FLOT for patients with gastric or gastroesophageal junction cancer.

At the 2023 Lymphoma, Leukemia & Myeloma Congress, Joseph Mikhael, MD, discusses treatment regimens like CELMoDs and XP01 inhibitors for patients with multiply relapsed multiple myeloma.

At the 2023 Lymphoma, Leukemia & Myeloma Congress, Joseph Mikhael, MD, participated in a debate on the benefits of minimal residual disease testing in multiple myeloma treatment.

Gilles Salles, MD, PhD, offers advice for fellow oncologists in the B-cell lymphoma space, highlighting the need for strategically chosen therapies to minimize the risk of transformations.

At the 65th ASH Annual Meeting, Lorenzo Falchi, MD, shares results which indicated that subcutaneous mosunetuzumab as first-line therapy demonstrated efficacious outcomes and manageable safety among patients with high-tumor burden FL.

At the 65th ASH Annual Meeting, Adrian Wiestner, MD, discusses exciting possibilities for the future of chronic lymphocytic leukemia treatment, including the prospect of time-limited treatment periods and T-cell-engaging bispecific antibodies.

At the 65th ASH Annual Meeting, Jeffrey Matous, MD, shared initial trial results that talquetamab plus pomalidomide demonstrated rapid, deep responses among patients with R/R multiple myeloma and ≥2 prior lines of therapy.

At the 65th ASH Annual Meeting in San Diego, California, Alina Markova, MD, shared study results that demonstrated ruxolitinib 1.5% cream was safe and effective compared to placebo in treating cutaneous nonsclerotic and superficially...

At the 65th ASH Annual Meeting, David Andorsky, MD, discussed updated findings from the Symphony-1 trial after a 22.5-month follow-up.

At the 65th ASH Annual Meeting, Alexey Danilov, MD, analyzes the prognostic value of undetectable MRD among patients with follicular lymphoma initially treated with chemotherapy.